Kornimate/medical-research-clean huggingface dataset:
biopsy size and pain perception during colposcopic biopsy

Conditions: Pain Uterus; Tenaculum

Summary: the investigators will investigate patients pain and biopsy size during colposcopic biopsy. the investigators will use tenaculum randomized patient with or without intracervical blockage.

the study was designed four arms. the investigators will perform colposcopy because of various causes. the first arm is used tenaculum and performed intracervical blockage. the second arm is not used tenaculum and performed intracervical blockage. the third arm is used tenaculum and not performed intracervical blockage. the fourth arm is not used tenaculum and not performed intracervical blockage and then we will study patients pain and biopsy size during colposcopic biopsy. pain reduce and biopsy size are very important for patient and diagnose of the cervix cancer.

Eligibility criteria:
inclusion criteria: * 18-80 year-old women who had colposcopic biopsy exclusion criteria: * had orthopedical problems * analgesic allergy * have previous cone biopsy * analgesic use until six hours before colposcopy * advanced cervicovaginal atrophy * linear visual analog score for pain is used
progesterone and brain imaging study

Conditions: Nicotine Dependence; Nicotine Withdrawal

Summary: male and female smokers were recruited to undergo 2 phases of smoking cessation. each phase was 4 days long and involved 3 brain-imaging scans, blood draws and an intervention involving progesterone or a matched placebo.

the purpose of this study is to learn whether a sex hormone called progesterone is helpful in reducing cigarette smoking and craving for cigarettes. this study also includes brain imaging to measure possible effects of progesterone on certain neurochemicals. these neurochemicals are called gamma-aminobutyric acid (or gaba for short) and glutamate. both nicotine and progesterone affect these brain chemicals. individuals wishing to participate in this study must be medically healthy men or women who smoke at least 10 cigarettes per day or greater. participants must not suffer from a mental illness or use drugs other than nicotine and marijuana. participants cannot have any implanted metallic devices such as pacemakers, orthodontic braces, or shrapnel. participants must not have peanut allergies and must never have had a reaction to progesterone. finally, participants cannot be taking any medications for anxiety, depression or insomnia.

Eligibility criteria:
inclusion criteria: * female and male smokers, aged 18 to 50 years; * history of smoking greater than or equal to 10 cigarettes daily for the past year, as per self-report (periods of smoking abstinence within the last year will be exclusionary at pi discretion); * not seeking treatment at the time of the study for nicotine dependence; * have a fagerstrom test for nicotine dependence (ftnd) score of at least 3 and a carbon monoxide (co) level greater than or equal to 11 ppm; * clean urine drug screen (marijuana is permissible); * in good health as verified by medical history; * for women, not pregnant as determined by pregnancy screening, nor breast feeding. exclusion criteria: * history of major medical illness: including liver diseases, abnormal vaginal bleeding, suspected or known malignancy; thrombophlebitis; deep vein thrombosis; pulmonary embolus; clotting or bleeding disorders; heart disease; diabetes; history of stroke or other medical conditions that the physician investigator deems as contraindicated for the patient to be in the study; * regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent (within previous year) psychiatric diagnosis and treatment for axis i disorders including major depression, bipolar affective disorder, generalized anxiety disorder, post-traumatic stress disorder and panic disorder; * lifetime history of schizophrenia or other psychotic disorder; * lifetime substance dependence disorder, excepting nicotine, alcohol and marijuana, as per scid interview * substance use disorders within the previous 2 years, excepting nicotine, as per scid interview * regular use of any other tobacco products than cigarettes, including smokeless tobacco and nicotine products; * known allergy to progesterone or peanuts (vehicle for micronized progesterone).

Keywords: nicotine smoking
novel biochemical and molecular determinants for soft tissue sarcoma

Conditions: Sarcoma

Summary: the purpose of this study is to study normal and sarcoma cells. to study these cells we need to have human tissue. you will be having or have already had a procedure to remove tissue. we would like to use some of this tissue. we will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. we will perform an extensive analysis of your samples. we will only use extra tissue left over after all needed testing has been done or remove an additional small amount of tissue if you are having a biopsy. we will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of sarcoma.

in this protocol, we plan to identify specific markers from biochemical, proteomic, epigenetic and molecular genetic analyses that predict clinical outcome, responsiveness to therapy and might serve as promising therapeutic targets in patients with soft tissue sarcoma.

Eligibility criteria:
inclusion criteria: * all patients with known or suspected sarcoma who will have or have had tissue removed for therapeutic or diagnostic purposes. * patients will be entered without preference for any particular racial/ethnic group or gender. * patients may have received prior hormonal therapy, cytotoxic chemotherapy, irradiation, immunotherapy or surgical therapy. * tissue specimens must be large enough in quantity to allow routine pathologic analysis, with the research laboratory specimen removed from the residual specimen, which would otherwise be discarded. optimal tissue amounts for snap freeze: core biopsy - 2 tissue cores incisional biopsy- 0.5 to 1.5 grams resected sarcoma specimen- 1.0 to 50 grams depending on size of specimen normal fat or muscle tissue - 0.5 to 4.0 grams (if available from resected sarcoma specimen) optimal tissue amounts for rna later core biopsy - 2 tissue cores incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes) resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) normal fat or muscle tissue - 30 mg (three 3 x 3 x 3 mm cube exclusion criteria: - none

Keywords: biochemical determinants molecular determinants
intracorporeal versus extracorporeal anastomosis in robotic right colectomy

Conditions: Colonic Cancer

Summary: right-sided colonic cancer is treated with right-sided colectomy, predominantly performed as minimally invasive surgery with extracorporeal anastomosis (eca). in recent years a new technique with intracorporeal anastomosis (ica) has emerged and it is thought that ica is less invasive and thereby has the potential to improve the postoperative course of right colonic cancer patients. the objective of this study is to compare robotic right colectomy with either ica or eca in a randomized controlled setting.


Eligibility criteria:
inclusion criteria: all patients scheduled for robotic right colectomy due to colonic cancer are eligible for inclusion.

Keywords: postoperative pain postoperative recovery intracorporeal anastomosis robotic right colectomy
safety and preliminary efficacy study of v404 pds in uveitis

Conditions: Uveitis, Posterior; Uveitis, Intermediate

Summary: this study is intended to evaluate the safety of v404 pds in patients with chronic non-infectious uveitis. secondarily, the study will evaluate whether v404 pds can provide clinically measurable benefit over an extended period of time in patients with chronic non-infectious uveitis.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * confirmed diagnosis of active uveitis * sufficient lens/media clarity * meet best-corrected visual acuity criteria * willing and able to use contraception exclusion criteria: * pregnant, breast feeding * uncontrolled glaucoma * intraocular surgery or periocular/intraocular injections within 6 weeks * periocular or intraocular steroid within 3 months * prior vitrectomy * prior corneal transplant * prior fluocinolone implant * allergy or sensitivity to study drug * participation in other trial within 30 days * abnormal liver function * history of positive serum tuberculosis test
penile ischemia for hypospadias repair and the patients and surgeons reported outcomes

Conditions: Hypospadias; Hypospadias, Coronal; Hypospadia, Repair; Tourniquet

Summary: although haemostasis aimed to maintain bloodless surgical field for better exposure for the surgeon, cosmetic impact, and decreased breakdown of repair, there is no trials regarding the impact of haemostasis techniques on surgeon satisfaction during surgery and patients reported outcomes.


Eligibility criteria:
inclusion criteria: * distal penile hypospadias were eligible for tubularized incided plate (tip) urethroplasty repair exclusion criteria: * coagulopathy * sickle cell disease or sickle cell trait * circumcised patient * history of previous failed surgery * severe chordee (\>30 degree after degloving).

Keywords: tourniquet hypospadias
development of a cellular biomarker for the diagnosis and treatment of diabetic foot ulcers

Conditions: Diabetic Foot Ulcer; Type 2 Diabetes

Summary: this project aims to result in the identification of such markers, and the development of a feasible quantitative method of distinguishing between tissue that has the capacity to heal and tissue that does not, thus identifying a non-healing phenotype.

the goal of this project is to identify objective, quantitative biological and molecular markers that correlate with healing outcomes for diabetic foot ulcers (dfus) using debrided tissue of patients with wounds. this project aims to result in the identification of such markers, and the development of a feasible quantitative method of distinguishing between tissue that has the capacity to heal and tissue that does not, thus identifying a non-healing phenotype. the ability to differentiate between healing and non-healing tissue at the onset of wound care will allow for the use of targeted therapies and earlier initiation of aggressive treatments where indicated.

Eligibility criteria:
inclusion criteria: * male or female, age ≥ 18 * type 2 diabetes * a break in the skin on the foot ≥ 0.5cm2 and is grade 1 or 2 as defined by the wagner grading system * hemoglobin a1c ≥ 5.9% * ability to provide written informed consent exclusion criteria: * any experimental drugs taken orally or topically within 4 weeks of study entry * malignant disease at/or in proximity to the dfu * target wound of malignant origin * failure to satisfy at least one inclusion criterion for one of the two study groups.
vap-pro-c6. effectiveness and tolerability of venoactive drugs in combination therapy in patients with cvd (ceap c6)

Conditions: Chronic Venous Insufficiency

Summary: the vap-pro-c6 is a russian multicenter observational program to be implemented at the routine visits and assessments. the program will include patients with chronic venous disease of ceap classes c6. this program is planned to be carried out in russia in 2021-2022.

aim of the program is to describe effectiveness and tolerability of systemic pharmacotherapy as a part of combination therapy and its effect on the overall treatment outcomes in patients with venous ulcers (ceap classes c6) treated in real clinical settings. the planned number of patients is 350. the inclusion period lasts for 6 months. the treatment will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation. the following objective methods will be used to assess the changes in the skin condition: * measurement of the area of reference ulcer (using lesionmeter\*) before and after the treatment; * changes in status localis. * the presence and location of venous reflux and/or occlusion. the study does not implicate any intervention to routine management of patients with chronic venous disease (cvd). in particular, in this study the parameters that are usually evaluated during the examination of patients with classes c6 cvd (ceap) will be recorded. special attention will be paid to evaluating changes of the area of referent vu using objective methods (measuring ulcer area using lesionmeter, time to ulcer healing). * lesionmeter is a generally available tool for measuring the venous ulcer area.

Eligibility criteria:
inclusion criteria: * cvd documented by venous dus * age over 18 years * written informed consent is provided * no treatment with venoactive drugs within 4 weeks prior to inclusion in the study * presence of a primary /active venous ulcer (class c6/ ceap) that meets criteria for the referent ulcer * no surgical intervention or procedure (including sclerotherapy) for cvd is planned exclusion criteria: * withdrawal of the informed consent * pregnancy or willingness to become pregnant within at least 2 months after the end of the study * indications for surgery (including sclerotherapy) * serious violation or non adherence to the prescribed therapy/ regimen * use of prohibited drugs that can cause edema of lower extremities (calcium channel blockers, hormonal agents, nsaids, etc.)
smart (school-aged children making healthy choices and recognizing stroke)

Conditions: Stroke

Summary: a stroke awareness program for school-aged children to learn the signs/symptoms of stroke, teach their parents and make healthy life-style choices.

1. to educate school-aged children, grades 9th through 12th on the f.a.s.t. (face, arm, speech and time) acronym, additional signs and symptoms of stroke and the need for immediate activation of emergency medical services (ems) by calling 911. 2. to improve adults' stroke literacy through educating their children in grades 9th through 12th.

Eligibility criteria:
inclusion criteria: * high-school student exclusion criteria: * not a high-school student

Keywords: stroke stroke prevention children education
a comparison of zidovudine plus lamivudine versus ddi used alone or in combination with zidovudine in hiv-1 infected children

Conditions: HIV Infections

Summary: to compare the efficacy of lamivudine (3tc) and zidovudine (azt) in combination versus the better of didanosine (ddi) monotherapy or ddi/azt combination, in symptomatic hiv-1 infected children who received less than 56 days of prior antiretroviral therapy. to evaluate the safety and tolerance of 3tc/azt in this patient population. to determine other measures of diseases in response to the study regimens. currently, none of the potential treatments for hiv-1 infection has proven to be both nontoxic and effective in long-term use. however, previous studies in both adults and children have shown that 3tc combined with azt reduced hiv load in blood and increased white blood cells. additionally, 3tc has demonstrated a favorable safety profile.

currently, none of the potential treatments for hiv-1 infection has proven to be both nontoxic and effective in long-term use. however, previous studies in both adults and children have shown that 3tc combined with azt reduced hiv load in blood and increased white blood cells. additionally, 3tc has demonstrated a favorable safety profile. patients are randomized to receive oral 3tc/azt, ddi/azt, or ddi alone for at least 24 months. per amendment 4/29/96: note: randomization to zdv+ddi arm was terminated in spring of 1996 based upon the results of actg 152. patients on that arm will continue on blinded study drug and will be followed until the end of the study.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * ivig. * prophylaxis for opportunistic infection. * epo. * g-csf or gm-csf. patients must have: * symptomatic hiv infection. * less than 56 days of prior antiretroviral therapy. * consent of parent or guardian. note: * co-enrollment on actg 219, actg 220, and certain actg opportunistic infection protocols is permitted. prior medication: allowed: * up to 56 days of prior antiretroviral therapy. * prior immunomodulator therapy. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * malignancy. * hypersensitivity to a nucleoside analog. * current grade 2 or higher amylase/lipase toxicity or grade 3 or 4 other toxicity. per amendment 4/29/96: * active opportunistic infection and/or serious bacterial infection at the time of entry. concurrent medication: excluded: * any other anti-hiv therapy. * megestrol acetate ( megace ). * probenecid. * iv pentamidine. * human growth hormone ( hgh ). * systemic corticosteroids for more than 2 weeks. prior medication: excluded: * investigational drug therapy within 14 days prior to study entry.

Keywords: didanosine drug therapy, combination acquired immunodeficiency syndrome aids-related complex zidovudine lamivudine
dexamethasone as an immediate intervention

Conditions: Trauma

Summary: to determine if a single dose of dexamethasone (5 mg) administered in the first 12 hours following a potentially traumatic event alters a) cortisol and fkbp5 rna the next day in the periphery measured in saliva; b) fkbp5 methylation by 1 month; c) executive functioning and emotion regulation functioning; d) psychophysiological (heart rate, respiration, skin conductance) in response cued reminders of the trauma; e) enhances the likelihood of remission of ptsd symptom severity.


Eligibility criteria:
inclusion criteria: * adults 18-70 years * evidence of acute post traumatic event (pte) exposure defined by diagnostic and statistical manual criterion 'a' * evidence of a significant stress response defined by dsm v ptsd criterion 'b' and meeting at least criteria for 'partial ptsd' or a minimum of 3 of 4 dsm v ptsd symptom criterion * score of 60 or higher on the subjective units of distress scale (suds) * living in new york tri-state area * fluency in english, spanish exclusion criteria: * admission to an intensive care unit or other overnight admission * in the emergency department for more than 6 hours * evidence of ongoing traumatic exposure (e.g. domestic violence) * evidence of psychotic symptoms * evidence of homicidality/suicidality * adults with an open head injury, a positive ct scan, loss of consciousness \>30 seconds or survivors in a coma * adults in police custody or department of correction (doc) patients * inability to understand the study's procedures, risks, or side effects, or otherwise unable to give informed consent. * females who are nursing or pregnant (as confirmed by a positive urine pregnancy test). * permanent cardiac pacer implant. * . self-reported medical conditions that may be affected by dex including asthma, epilepsy,diabetes, liver disease, kidney disease, thyroid disorder, muscle disorder, history of malaria,tuberculosis, osteoporosis, glaucoma or cataracts. * self-reported adverse reactions to steroids

Keywords: ptsd (post traumatic stress disorder) emergency department
assessment of functional ability and follow-up at home for older medical patients

Conditions: Geriatric Disorder

Summary: the aim of this study is to examine the effect of an intervention that consist of assessment of functional ability, rehabilitation plan and follow-up at home for older medical patients. the hypothesis is that assessment of functional ability, development of rehabilitation plan and follow-up at home reduce the older medical patient's risk of readmission. also the intervention is expected to reduce mortality, number of contacts to general practitioners and emergency physician


Eligibility criteria:
inclusion criteria: * patients admitted to medical visitations section (mva) aarhus university hospital * aged 65+ * resident in city of aarhus exclusion criteria: * patients admitted from nursing home * patients transferred to other hospital departments * patients terminally ill

Keywords: functional assessment readmission acute care older medical patients
early remote at-risk diagnosis for cerebral palsy in follow-up clinics for high-risk infants

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is the most common motor dysfunction in childhood. traditionally, diagnosis is set between 12 and 24 months of age. this study will evaluate feasibility of a new screening procedure for early detection of cp in high-risk infants and investigate how such a procedure can be implemented in the central norwegian regional health authority (cnrha). the most accurate method to detect and predict cp at an early age is the general movement assessment (gma). gma is based upon expert observations of infant spontaneous movements in a video. in central-norway such expertise is today only present at st. olavs hospital, trondheim university hospital. video recordings by health personnel and parents will be used in follow-up programs within cnrha for remote expert based gma. in addition, machine learning models will be applied for automatic detection of cp. early identification of cp will lead to improved function and increased possibility to direct health care resources to the patients who need it most, independent of geographical and expert based constraints.


Eligibility criteria:
inclusion criteria: * hospitalized at a neonatal intensive care unit (nicu) within the central norway regional health authority that is referred to follow-up in the specialist health services containing a team of minimum a pediatrician and a physiotherapist. * at high-risk for adverse neurological outcomes as considered by the pediatrician on the basis of clinical judgement (example: serious asphyxia, prematurity, stroke, brain hemorrhage) exclusion criteria: * peripheral neuromotor disease e.g. brachial plexus injury * iatrogenic restricted movements (e.g. cast for clubfoot)

Keywords: diagnosis videos smartphone app movement movement disorders infants
satavaptan dose-ranging study in normonatraemic patients with cirrhotic ascites

Conditions: Ascites; Liver Cirrhosis

Summary: the primary objective is to determine the optimal dose or range of doses of sr121463b for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide. the secondary objective is to determine the tolerability of different fixed doses of sr121463b over a 14 day treatment period in cirrhotic ascites.


Eligibility criteria:
inclusion criteria: * cirrhosis of the liver confirmed by ultrasound, endoscopic examination or biochemical evidence * moderate or tense ascites * serum sodium of \>130 mmol/l. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: cirrhotic ascites